By Sheeba M. | June 12, 2026
Cannabis ETF Flows Hit 6-Month High as Institutional Buyers Return
Cannabis equity exchange-traded funds registered net inflows of $487 million in May 2026, marking a significant reversal from the negative flows that plagued the sector for the previous eight months. The rebound reflects a shift in institutional sentiment toward cannabis MSOs, which are trading at historically depressed valuations relative to peer groups and showing measurable progress toward sustainable profitability.
The Horizons Marijuana Life Sciences ETF (TSX: HMMJ) and the ETFMG Alternative Harvest ETF (NYSE: MJX) both posted their strongest monthly inflows since late 2025. HMMJ added $156 million, while MJX captured $203 million—accounting for 73% of total industry flows. These moves suggest that large asset managers are building positions ahead of what many view as a near-term catalyst: federal legalization progress or strong Q2 earnings from multi-state operators.
Why Now? The Valuation Arbitrage
Cannabis operators are currently trading at a 12-15x forward P/E discount to the S&P 500 despite posting higher EBITDA growth rates and expanding margins. Tilray, Ayr Wellness, and Truss Innovation each reported double-digit year-over-year EBITDA growth in their most recent quarters. This discrepancy—profitability growth outpacing valuation—is precisely what institutional investors exploit.
Additionally, state-level regulatory easing in California, Illinois, and New York has reduced supply-side headwinds. Retail pricing has stabilized 8-12% above Q1 levels, improving cash flow visibility for investors who track average selling price (ASP) trends.
ETF Composition Shift
Fund managers are reweighting cannabis ETFs toward profitability. Holdings in Tilray increased by 340 basis points in MJX’s top 10, while exposure to loss-making ancillary companies was trimmed. This concentration play signals that professional allocators believe the “survival of the fittest” phase is ending and the “winner consolidation” phase is beginning.
Retail investor participation remains muted—retail accounts represented just 23% of ETF flows last month, down from 47% during the 2021 boom. This is bullish for price discovery, as it means current inflows are driven by conviction capital rather than speculation.
What Could Break This Momentum?
The risk is federal legalization itself. If Congress acts decisively, large pharma and beverage companies could enter the market with superior branding and distribution, squeezing cannabis operators’ margins despite volume growth. However, most Street analysts view this as a 2027+ event, giving institutional holders a 12-18 month runway to accumulate before any structural disruption.
Sources
- SEC ETF Filings — Monthly inflow data
- Bloomberg Terminal — Cannabis equity flows and valuations
- Tilray Investor Relations — Comparative profitability metrics
Track cannabis stocks with the Weedstock Real-Time Tracker